HROW250117P50000
- 16.40
- +1.70+11.56%
Harrow Newsroom
Harrow Health (HROW) Gets a Buy From Craig-Hallum
Harrow Appoints Amir H. Shojaei as Chief Scientific Officer
B.Riley Financial Maintains Harrow(HROW.US) With Buy Rating, Cuts Target Price to $69
Express News | Harrow Inc : B. Riley Cuts Target Price to $69 From $73
10 Health Care Stocks With Whale Alerts In Today's Session
Harrow Bengaluru Hosts Inspiring Event to Pioneer Future-Ready Education
OSRX, Inc. Responds to Jury Verdict in Trademark Infringement Case
Craig-Hallum Sticks to Its Buy Rating for Harrow Health (HROW)
Harrow's Unit Wins Trademark Infringement Case Against OSRX
Express News | Harrow’s Imprimisrx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in Imprimisrx, LLC V. Osrx, Inc.
Former Harrow Unit Melt Announces Results for MELT-300 to Sedate for Surgery
Express News | Harrow Inc - Melt-300 Shows Statistical Superiority Over Midazolam and Placebo
Express News | Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for Melt-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
Lake Street Initiates Harrow(HROW.US) With Buy Rating, Announces Target Price $55
Harrow Health's Strategic Transformation and Growth Potential Underscore Buy Rating
US Manufacturing Index Rises To 43, Highest Since 2020
Harrow Announces Participation in Upcoming Investor Conferences
Q3 2024 Harrow Inc Earnings Call
Harrow Inc. Reports Strong Q3 2024 Growth